Changes to the Code
H.R. 8983 · PETS Act · Introduced The text as a member of Congress first filed it. Most bills never get further than this.
In committee · step 2 of 5
42 U.S.C. § 280g–3 Prescription drug monitoring program
7 changes the bill asks for here, 6 carried out
- Not carried out:
by striking Nothing in this section and inserting the following:(1) In general.— Except as specified in paragraph (2), nothing in this section; and
The bill gives this provision a heading and rewords it at the same time, a kind of change we can't show yet.
Technical detail
the provision inserted says more than a heading and the words struck - Carried out:
by adding at the end the following:
(2) Veterinary patients.— (A) In general.— Paragraph (1) shall not apply with respect to the authority of a State to prohibit reporting to the PDMP of the dispensing of a controlled substance to a minor patient, if— (i) the prescribing or dispensing practitioner is a …
The section already has a provision under this letter or number, so it would have two.
- Carried out:
Section 399O(k)(3) of the Public Health Service Act (42 U.S.C. 280g–3(k)(3)) is amended by striking
physician,
and insertingphysician, veterinarian,
. - Carried out:
in paragraph (5), by striking
and
at the end; - Carried out:
in paragraph (6), by striking the period at the end and inserting
; and
; and - Carried out:
by adding at the end the following:
(7) the reporting to the PDMP by each prescribing or dispensing practitioner, or their designee, of any instance of a non-fatal overdose event that required intervention by such practitioner (or designee), not later than 72 hours after such overdose event occurred..
- Carried out:
Section 399O(c)(2) of the Public Health Service Act (42 U.S.C. 280g–3(c)(2)) is amended by striking
may
and insertingshall
.
This bill puts a provision under a letter or number this section already uses, so the section would have two. The law has probably changed since the bill was written.
§ 280g–3(b)–(c)
Start of § 280g–3 to (b)(3) unchanged
| Where | Mark | The Code now | Mark | As the bill would leave it |
|---|---|---|---|---|
| (b)(4) | (4) | (4) | ||
| the proactive notification to a practitioner when patterns indicative of controlled substance misuse by a patient, including opioid misuse, are detected; | the proactive notification to a practitioner when patterns indicative of controlled substance misuse by a patient, including opioid misuse, are detected; | |||
| (b)(5) | (5) | (5) | ||
| the availability of data in the PDMP to other States, as allowable under State law; | the availability of data in the PDMP to other States, as allowable under State law; | |||
| (b)(6) | (6) | (6) | ||
| the availability of nonidentifiable information to the Centers for Disease Control and Prevention for surveillance, epidemiology, statistical research, or educational purposes | the availability of nonidentifiable information to the Centers for Disease Control and Prevention for surveillance, epidemiology, statistical research, or educational purposes[inserted: ; and] | |||
| (b)(7) | (7) [inserted: ] | |||
| [inserted: the reporting to the PDMP by each prescribing or dispensing practitioner, or their designee, of any instance of a non-fatal overdose event that required intervention by such practitioner (or designee), not later than 72 hours after such overdose event occurred.] | ||||
| (c) | (c) Drug misuse and abuse | (c) Drug misuse and abuse | ||
| In consultation with practitioners, dispensers, and other relevant and interested stakeholders, a State receiving support under this section— | In consultation with practitioners, dispensers, and other relevant and interested stakeholders, a State receiving support under this section— | |||
| (c)(1) | (1) | (1) | ||
| shall establish a program to notify practitioners and dispensers of information that will help to identify and prevent the unlawful diversion or misuse of controlled substances; | shall establish a program to notify practitioners and dispensers of information that will help to identify and prevent the unlawful diversion or misuse of controlled substances; | |||
| (c)(2) | (2) | (2) | ||
| [inserted: shall], to the extent permitted under State law, notify the appropriate authorities responsible for carrying out drug diversion investigations if the State determines that information in the PDMP maintained by the State indicates an unlawful diversion or abuse of a controlled substance; | ||||
| (c)(3) | (3) | (3) | ||
| may conduct analyses of controlled substance program data for purposes of providing appropriate State agencies with aggregate reports based on such analyses in as close to real-time as practicable, regarding prescription patterns flagged as potentially presenting a risk of misuse, abuse, addiction, overdose, and other aggregate information, as appropriate and in compliance with applicable Federal and State laws and provided that such reports shall not include protected health information; and | may conduct analyses of controlled substance program data for purposes of providing appropriate State agencies with aggregate reports based on such analyses in as close to real-time as practicable, regarding prescription patterns flagged as potentially presenting a risk of misuse, abuse, addiction, overdose, and other aggregate information, as appropriate and in compliance with applicable Federal and State laws and provided that such reports shall not include protected health information; and | |||
| (c)(4) | (4) | (4) | ||
| may access information about prescriptions, such as claims data, to ensure that such prescribing and dispensing history is updated in as close to real-time as practicable, in compliance with applicable Federal and State laws and provided that such information shall not include protected health information. | may access information about prescriptions, such as claims data, to ensure that such prescribing and dispensing history is updated in as close to real-time as practicable, in compliance with applicable Federal and State laws and provided that such information shall not include protected health information. | |||
§ 280g–3(h)–(i)
(d)–(h) unchanged
| Where | Mark | The Code now | Mark | As the bill would leave it |
|---|---|---|---|---|
| (h)(4) | (4) No Federal private cause of action | (4) No Federal private cause of action | ||
| Nothing in this section shall be construed to create a Federal private cause of action. | Nothing in this section shall be construed to create a Federal private cause of action. | |||
| (h)(5) | (5) Promoting State choice | (5) Promoting State choice | ||
| Nothing in this section shall be construed to authorize the Secretary to require States to use a specific vendor or a specific interoperability connection other than to align with nationally recognized, consensus-based open standards, such as in accordance with sections 300jj–11 and 300jj–14 of this title. | Nothing in this section shall be construed to authorize the Secretary to require States to use a specific vendor or a specific interoperability connection other than to align with nationally recognized, consensus-based open standards, such as in accordance with sections 300jj–11 and 300jj–14 of this title. | |||
| (h)(2) | (2) [inserted: Veterinary patients.—] | |||
| (h)(2)(A) | (A) [inserted: In general.—] | |||
| [inserted: Paragraph (1) shall not apply with respect to the authority of a State to prohibit reporting to the PDMP of the dispensing of a controlled substance to a minor patient, if—] | ||||
| (h)(2)(A)(i) | (i) [inserted: ] | |||
| [inserted: the prescribing or dispensing practitioner is a veterinarian licensed in such State; and] | ||||
| (h)(2)(A)(ii) | (ii) [inserted: ] | |||
| [inserted: the patient to whom the controlled substance is prescribed or dispensed is a veterinary patient.] | ||||
| (h)(2)(B) | (B) [inserted: Information to be reported.—] | |||
| [inserted: A veterinarian described in subparagraph (A) shall report to the PDMP, in lieu of information required under this section relating to the veterinary patient involved, such information relating to the owner or primary caretaker of the veterinary patient.] | ||||
| (i) | (i) Progress report | (i) Progress report | ||
| Not later than 3 years after October 24, 2018, the Secretary shall— | Not later than 3 years after October 24, 2018, the Secretary shall— | |||
| (i)(1) | (1) | (1) | ||
| complete a study that— | complete a study that— | |||
§ 280g–3(k)Definitions(2)–(5)
(i)(1)(A)–(k)(1) unchanged
| Where | Mark | The Code now | Mark | As the bill would leave it |
|---|---|---|---|---|
| (2) | (2) | (2) | ||
| The term “dispense” means to deliver a controlled substance to an ultimate user by, or pursuant to the lawful order of, a practitioner, irrespective of whether the dispenser uses the Internet or other means to effect such delivery. | The term “dispense” means to deliver a controlled substance to an ultimate user by, or pursuant to the lawful order of, a practitioner, irrespective of whether the dispenser uses the Internet or other means to effect such delivery. | |||
| (3) | (3) | (3) | ||
| The term “dispenser” means a physician, pharmacist, or other person that dispenses a controlled substance to an ultimate user. | The term “dispenser” means a physician, [inserted: veterinarian, ]pharmacist, or other person that dispenses a controlled substance to an ultimate user. | |||
| (4) | (4) | (4) | ||
| The term “interstate interoperability” with respect to a PDMP means the ability of the PDMP to electronically share reported information with another State if the information concerns either the dispensing of a controlled substance to an ultimate user who resides in such other State, or the dispensing of a controlled substance prescribed by a practitioner whose principal place of business is located in such other State. | The term “interstate interoperability” with respect to a PDMP means the ability of the PDMP to electronically share reported information with another State if the information concerns either the dispensing of a controlled substance to an ultimate user who resides in such other State, or the dispensing of a controlled substance prescribed by a practitioner whose principal place of business is located in such other State. | |||
| (5) | (5) | (5) | ||
| The term “intrastate interoperability” with respect to a PDMP means the integration of PDMP data within electronic health records and health information technology infrastructure or linking of a PDMP to other data systems within the State, including the State’s Medicaid program, workers’ compensation programs, and medical examiners or coroners. | The term “intrastate interoperability” with respect to a PDMP means the integration of PDMP data within electronic health records and health information technology infrastructure or linking of a PDMP to other data systems within the State, including the State’s Medicaid program, workers’ compensation programs, and medical examiners or coroners. |
Rest of § 280g–3 unchanged